{"id":75304,"date":"2026-08-19T12:17:40","date_gmt":"2026-08-19T04:17:40","guid":{"rendered":"https:\/\/flcube.com\/?p=75304"},"modified":"2026-08-19T12:17:42","modified_gmt":"2026-08-19T04:17:42","slug":"betta-pharmaceuticals-partner-eyepoint-reports-eyp-1901-misses-primary-endpoint-in-first-pivotal-phase-iii-lugano-trial-for-wet-amd-duravyu-fails-non-inferiority-vs-afliberc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75304","title":{"rendered":"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Betta Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/300558:SHE\">SHE: 300558<\/a>) announced that its partner <strong>EyePoint Pharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/EYPT:NASDAQ\">NASDAQ: EYPT<\/a>) disclosed data from <strong>LUGANO<\/strong>, the first of two pivotal <strong>Phase III clinical trials<\/strong> evaluating <strong>EYP\u20111901<\/strong> (vorolanib ophthalmic insert, brand name: <strong>DURAVYU<\/strong>), an investigational <strong>intravitreal insert<\/strong> for the treatment of <strong>wet age\u2011related macular degeneration (wAMD)<\/strong>. The study <strong>did not achieve its pre\u2011specified primary endpoint<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-trial-outcome-summary\" class=\"wp-block-heading\">Trial Outcome Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Name<\/strong><\/td><td>LUGANO (first of two pivotal Phase III trials)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>EYP\u20111901 \/ DURAVYU (vorolanib ophthalmic insert)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Wet age\u2011related macular degeneration (wAMD)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Intravitreal insert<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Aflibercept 2 mg, administered per labeled indication<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Primary endpoint <strong>not met<\/strong>; non\u2011inferiority not demonstrated<\/td><\/tr><tr><td><strong>Disclosure Date<\/strong><\/td><td>18 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-primary-endpoint-design\" class=\"wp-block-heading\">Primary Endpoint Design<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Endpoint:<\/strong> Mean change in <strong>Best Corrected Visual Acuity (BCVA)<\/strong> from baseline<\/li>\n\n\n\n<li><strong>Assessment Period:<\/strong> Pooled period from <strong>Day 1 to Weeks 52 and 56<\/strong><\/li>\n\n\n\n<li><strong>Non\u2011Inferiority Margin:<\/strong> <strong>\u20114.5 letters<\/strong><\/li>\n\n\n\n<li><strong>Objective:<\/strong> Demonstrate non\u2011inferiority of <strong>DURAVYU<\/strong> versus <strong>aflibercept 2 mg<\/strong><\/li>\n\n\n\n<li><strong>Outcome:<\/strong> Based on the <strong>complete trial dataset<\/strong>, DURAVYU <strong>failed to demonstrate non\u2011inferiority<\/strong> relative to aflibercept<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-partnership-structure-amp-greater-china-rights\" class=\"wp-block-heading\">Partnership Structure &amp; Greater China Rights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agreement Date<\/strong><\/td><td>May 2022<\/td><\/tr><tr><td><strong>Parties<\/strong><\/td><td>Betta Pharmaceuticals \u00d7 EyePoint Pharmaceuticals<\/td><\/tr><tr><td><strong>Betta&#8217;s Rights<\/strong><\/td><td>Exclusive development and commercialization of <strong>EYP\u20111901<\/strong> in <strong>Greater China<\/strong> (Mainland China, Hong Kong, Macao, and Taiwan)<\/td><\/tr><tr><td><strong>EyePoint&#8217;s Rights<\/strong><\/td><td>Ophthalmic rights for EYP\u20111901 in the rest of the world<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Second Pivotal Trial Pending:<\/strong> LUGANO is the first of <strong>two pivotal Phase III trials<\/strong>; results from the second study will be critical in determining the overall development fate of the EYP\u20111901 program.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> The wAMD market is dominated by anti\u2011VEGF injectables including aflibercept, ranibizumab and newer long\u2011acting agents; a sustained\u2011release insert would have differentiated on <strong>treatment burden reduction<\/strong> had efficacy held up.<\/li>\n\n\n\n<li><strong>Greater China Exposure:<\/strong> The outcome directly affects <strong>Betta Pharmaceuticals&#8217;<\/strong> exclusive regional program, raising questions about development timelines and commercial planning across Mainland China, Hong Kong, Macao, and Taiwan.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> EyePoint&#8217;s next steps on the second pivotal trial, potential protocol or dosing adjustments, and any regulatory engagement regarding the path forward.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory outcomes, and commercial expectations for EYP\u20111901 (DURAVYU). Actual results may differ due to risks including additional trial results, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u5408\u4f5c\u4f19\u4f34EyePoint\u516c\u5e03DURAVYU\u6cbb\u7597\u6e7f\u6027\u5e74\u9f84\u76f8\u5173\u6027\u9ec4\u6591\u53d8\u6027\u5f00\u5c55\u7684\u4e24\u9879\u5173\u952eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u9996\u9879\u8bd5\u9a8c\u6570\u636e\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u5408\u4f5c\u4f19\u4f34EyePoint\u516c\u5e03DURAVYU\u6cbb\u7597\u6e7f\u6027\u5e74\u9f84\u76f8\u5173\u6027\u9ec4\u6591\u53d8\u6027\u5f00\u5c55\u7684\u4e24\u9879\u5173\u952eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u9996\u9879\u8bd5\u9a8c\u6570\u636e\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-9b7c5e8e-9b85-4a19-bf10-3eec6b1ea43d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u5408\u4f5c\u4f19\u4f34EyePoint\u516c\u5e03DURAVYU\u6cbb\u7597\u6e7f\u6027\u5e74\u9f84\u76f8\u5173\u6027\u9ec4\u6591\u53d8\u6027\u5f00\u5c55\u7684\u4e24\u9879\u5173\u952eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u9996\u9879\u8bd5\u9a8c\u6570\u636e\u7684\u516c\u544a.pdf\">\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u5408\u4f5c\u4f19\u4f34EyePoint\u516c\u5e03DURAVYU\u6cbb\u7597\u6e7f\u6027\u5e74\u9f84\u76f8\u5173\u6027\u9ec4\u6591\u53d8\u6027\u5f00\u5c55\u7684\u4e24\u9879\u5173\u952eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u9996\u9879\u8bd5\u9a8c\u6570\u636e\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u5408\u4f5c\u4f19\u4f34EyePoint\u516c\u5e03DURAVYU\u6cbb\u7597\u6e7f\u6027\u5e74\u9f84\u76f8\u5173\u6027\u9ec4\u6591\u53d8\u6027\u5f00\u5c55\u7684\u4e24\u9879\u5173\u952eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u9996\u9879\u8bd5\u9a8c\u6570\u636e\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9b7c5e8e-9b85-4a19-bf10-3eec6b1ea43d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its partner EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[231,17,516,1248,44,1030],"class_list":["post-75304","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-betta-pharmaceuticals","tag-clinical-trial-results","tag-eyepoint-pharmaceuticals","tag-nasdaq-eypt","tag-ophthalmology","tag-she-300558"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its partner EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) disclosed data from LUGANO, the first of two pivotal Phase III clinical trials evaluating EYP\u20111901 (vorolanib ophthalmic insert, brand name: DURAVYU), an investigational intravitreal insert for the treatment of wet age\u2011related macular degeneration (wAMD). The study did not achieve its pre\u2011specified primary endpoint.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75304\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept\" \/>\n<meta property=\"og:description\" content=\"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its partner EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) disclosed data from LUGANO, the first of two pivotal Phase III clinical trials evaluating EYP\u20111901 (vorolanib ophthalmic insert, brand name: DURAVYU), an investigational intravitreal insert for the treatment of wet age\u2011related macular degeneration (wAMD). The study did not achieve its pre\u2011specified primary endpoint.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75304\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T04:17:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T04:17:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75304#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75304\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept\",\"datePublished\":\"2026-08-19T04:17:40+00:00\",\"dateModified\":\"2026-08-19T04:17:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75304\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Betta Pharmaceuticals\",\"Clinical trial results\",\"EyePoint Pharmaceuticals\",\"NASDAQ: EYPT\",\"Ophthalmology\",\"SHE: 300558\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75304#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75304\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75304\",\"name\":\"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T04:17:40+00:00\",\"dateModified\":\"2026-08-19T04:17:42+00:00\",\"description\":\"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its partner EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) disclosed data from LUGANO, the first of two pivotal Phase III clinical trials evaluating EYP\u20111901 (vorolanib ophthalmic insert, brand name: DURAVYU), an investigational intravitreal insert for the treatment of wet age\u2011related macular degeneration (wAMD). The study did not achieve its pre\u2011specified primary endpoint.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75304#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75304\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75304#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept - Insight, China&#039;s Pharmaceutical Industry","description":"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its partner EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) disclosed data from LUGANO, the first of two pivotal Phase III clinical trials evaluating EYP\u20111901 (vorolanib ophthalmic insert, brand name: DURAVYU), an investigational intravitreal insert for the treatment of wet age\u2011related macular degeneration (wAMD). The study did not achieve its pre\u2011specified primary endpoint.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75304","og_locale":"en_US","og_type":"article","og_title":"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept","og_description":"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its partner EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) disclosed data from LUGANO, the first of two pivotal Phase III clinical trials evaluating EYP\u20111901 (vorolanib ophthalmic insert, brand name: DURAVYU), an investigational intravitreal insert for the treatment of wet age\u2011related macular degeneration (wAMD). The study did not achieve its pre\u2011specified primary endpoint.","og_url":"https:\/\/flcube.com\/?p=75304","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T04:17:40+00:00","article_modified_time":"2026-08-19T04:17:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75304#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75304"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept","datePublished":"2026-08-19T04:17:40+00:00","dateModified":"2026-08-19T04:17:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75304"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Betta Pharmaceuticals","Clinical trial results","EyePoint Pharmaceuticals","NASDAQ: EYPT","Ophthalmology","SHE: 300558"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75304#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75304","url":"https:\/\/flcube.com\/?p=75304","name":"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T04:17:40+00:00","dateModified":"2026-08-19T04:17:42+00:00","description":"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its partner EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) disclosed data from LUGANO, the first of two pivotal Phase III clinical trials evaluating EYP\u20111901 (vorolanib ophthalmic insert, brand name: DURAVYU), an investigational intravitreal insert for the treatment of wet age\u2011related macular degeneration (wAMD). The study did not achieve its pre\u2011specified primary endpoint.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75304#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75304"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75304#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Betta Pharmaceuticals Partner EyePoint Reports EYP\u20111901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD \u2013 DURAVYU Fails Non\u2011Inferiority vs. Aflibercept"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75304"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75304\/revisions"}],"predecessor-version":[{"id":75307,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75304\/revisions\/75307"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}